坦桑尼亚农村HIV感染者抗逆转录病毒药物与合并用药间临床显著药物相互作用的识别与管理
该前瞻性问卷研究纳入坦桑尼亚农村KIULARCO队列中334名接受抗逆转录病毒治疗且使用至少1种合并用药的成人,用利物浦药物相互作用数据库核对处方与医生问卷回答。129人存在至少1项临床相关药物相互作用,其中56人(43%)未被识别或管理不当;合并至少1种非传染性疾病与未识别/管理不当风险升高相关(OR=15.8;95%CI=1.8-139.6)。
要点
- HIV感染者合并用药中临床显著药物相互作用常见,识别与管理常不到位。
- 合并至少1种非传染性疾病者未识别或管理不当风险更高。
- 需加强教育、药物警戒并改善药物与监测可及性。
核心结论
- 在资源有限地区,抗逆转录病毒药物与合并用药间临床显著药物相互作用的识别和适当管理不理想。
- 应开展教育项目、药物警戒活动并增加药物和监测选项的可及性。
研究设计与样本
- 前瞻性问卷研究,2017年3月至7月在坦桑尼亚Ifakara慢性病诊所纳入接受抗逆转录病毒治疗且使用至少1种合并用药的成人。
- 共纳入334名参与者,中位年龄47岁(IQR=40-56岁),69%为女性,82%有至少1种非传染性疾病。
- 医生用结构化问卷识别潜在临床显著药物相互作用、给出管理建议并指出实施障碍,处方随后用利物浦药物相互作用数据库筛查比对。
主要发现
- 129名参与者存在至少1项临床相关药物相互作用,其中56名(43%)未被识别和/或管理不当。
- 56名中6名(11%)因监测选项有限或药物可负担性问题所致。
- 多变量logistic回归中,存在至少1种非传染性疾病与未识别/管理不当的药物相互作用风险升高相关(OR=15.8;95%CI=1.8-139.6)。
临床怎么用
- 对接受抗逆转录病毒治疗的HIV感染者应系统筛查合并用药中的临床显著药物相互作用。
- 合并非传染性疾病者尤需关注药物相互作用识别与正确管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The extent to which drug-drug interactions (DDIs) between antiretrovirals (ARVs) and co-medications are recognized and managed has not been thoroughly evaluated in limited-resource settings. OBJECTIVES: This prospective questionnaire-based study aimed to determine the prevalence and risk factors for unrecognized/incorrectly managed DDIs in people living with HIV followed-up at the Chronic Diseases Clinic of Ifakara (CDCI) and enrolled in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO). METHODS: We prospectively included ARV-treated adults receiving ≥1 co-medication coming for a follow-up visit at the CDCI between March and July 2017. Using a structured questionnaire, physicians were requested to identify potentially clinically significant DDIs in the prescribed treatment, to provide recommendations for their management and to indicate any hurdles to implement the recommendations. Prescriptions were subsequently screened for DDIs using the Liverpool DDIs database. Identified clinically significant DDIs and their recommended management according to the DDIs database were compared with the information provided in the questionnaires. RESULTS: Among 334 participants, the median age was 47 years (IQR = 40-56 years), 69% were female and 82% had ≥1 non-communicable disease (NCD). Overall, 129 participants had ≥1 clinically relevant DDI, which was not recognized and/or incorrectly managed in 56 participants (43%). Of those, 6 (11%) were due to limited monitoring options or medication affordability issues. In the multivariable logistic regression, the presence of ≥1 NCD was associated with an increased risk for unrecognized/incorrect DDI management (OR = 15.8; 95% CI = 1.8-139.6). CONCLUSIONS: Recognition/appropriate management of DDIs is suboptimal, highlighting the need for educational programmes, pharmacovigilance activities and increased access to medications and monitoring options. This should become a focus of HIV programmes given the increasing burden of NCDs in sub-Saharan Africa.
引用
- Kuemmerle A, Sikalengo G, Vanobberghen F, et al. Recognition and management of clinically significant drug-drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study. J Antimicrob Chemother. 2021. PMID: 34337653. doi:10.1093/jac/dkab254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。